Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: Implications for the antiphospholipid syndrome

Thrombosis and Haemostasis

Volumn 113, Issue 5, 2015, Pages 1071-1083

  Müller Calleja, Nadine ^a   Köhler, Antonia ^a   Siebald, Benjamin ^a   Canisius, Antje ^a   Orning, Carolin ^a   Radsak, Markus ^a   Stein, Pamela ^a   Mönnikes, René ^a   Lackner, Karl J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Antiphospholipid syndrome; Autoimmunity; Endosomal ROS generation; Monocytes; Thrombosis

Indexed keywords

IMMUNOGLOBULIN G; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PHOSPHOLIPID ANTIBODY; SUPEROXIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; CARRIER PROTEIN; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NLRP3 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DNA TRANSCRIPTION; ENDOSOME; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; AGED; ANIMAL; ANTIPHOSPHOLIPID SYNDROME; BLOOD; C57BL MOUSE; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SPLEEN; THROMBOSIS;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; CARRIER PROTEINS; CASPASE 1; ENDOSOMES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMASOMES; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MIDDLE AGED; MONOCYTES; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; SPLEEN; SUPEROXIDES; THROMBOSIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84931291695     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-07-0628     Document Type: Article

References (51)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.
2. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
3. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033–1044.
4. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330–339.
5. Willis R, Pierangeli SS. Anti-β2-glycoprotein I antibodies. Ann NY Acad Sci 2013; 1285: 44–58.
6. Du VX, Kelchtermans H, de Groot PG, et al. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 2013; 132: 319–326.
7. von Landenberg C, Lackner KJ, von Landenberg P, et al. Isolation and characterisation of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999; 13: 215–223.
8. Buschmann C, Fischer C, Ochsenhirt V, et al. Generation and characterisation of three monoclonal IgM antiphospholipid antibodies recognizing different phospholipid antigens. Ann NY Acad Sci 2005; 1051: 240–254.
9. Prinz N, Hauser F, Lorenz M, et al. Structural and functional characterisation of a human IgG monoclonal antiphospholipid antibody. Immunobiology 2011; 216: 145–151.
10. Lackner KJ, von Landenberg C, Barlage S, et al. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity. Thromb Haemost 2000; 83: 583–588.
11. Prinz N, Clemens N, Strand D, et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118: 2322–2332.
12. Prinz N, Clemens N, Canisius A, et al. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost 2013; 109: 525–531.
13. Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009; 214: 683–691.
14. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821–832.
15. Petrilli V, Dostert C, Muruve DA, et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615–622.
16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397–411.
17. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Sem Immunol 2009; 21: 242–253.
18. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229–265.
19. Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol 2010; 10: 123–130.
20. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11: 395–402.
21. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103–107.
22. Fernandes-Alnemri T, Yu JW, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509–513.
23. Kerur N, Veettil MV, Sharma-Walia N, et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 2011; 9: 363–375.
24. Gross O, Thomas CJ, Guarda G, et al. The inflammasome: an integrated view. Immunol Rev 2011; 243: 136–151.
25. Kostura MJ, Tocci MJ, Limjuco G, et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci USA 1989; 86: 5227–5231.
26. Rice AP, Kostura M, Mathews MB. Identification of a 90-kDa polypeptide which associates with adenovirus VA RNAI and is phosphorylated by the doublestranded RNA-dependent protein kinase. J Biol Chem 1989; 264: 20632–20637.
27. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417–426.
28. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol Med 2011; 17: 57–64.
29. Ben-Sasson SZ, Hu-Li J, Quiel J, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009; 106: 7119–7124.
30. Maliszewski CR, Sato TA, Vanden Bos T, et al. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1– and IL- 4-induced B cell activities in vitro. J Immunol 1990; 144: 3028–3033.
31. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89–102.
32. Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signalling. Immunity 2009; 30: 576–587.
33. Kryczek I, Wei S, Vatan L, et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007; 179: 1423–1426.
34. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942–949.
35. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012; 2012: 819467.
36. Martinon F. Signalling by ROS drives inflammasome activation. Eur J Immunol 2010; 40: 616–619.
37. Netea MG, van de Veerdonk FL, Kullberg BJ, et al. The role of NLRs and TLRs in the activation of the inflammasome. Expert Opin Biol Ther 2008; 8: 1867–1872.
38. Doring Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010; 215: 230–241.
39. Jourdan T, Godlewski G, Cinar R, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013; 19: 1132–1140.
40. Pollock JD, Williams DA, Gifford MA, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9: 202–209.
41. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749–3752.
42. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443–451.
43. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002; 3: 196–200.
44. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408: 740–745.
45. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med 1995; 182: 751–758.
46. Miller FJ, Jr., Filali M, Huss GJ, et al. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signalling endosomes containing Nox1 and ClC-3. Circ Res 2007; 101: 663–671.
47. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183: 787–791.
48. Bakimer R, Fishman P, Blank M, et al. Induction of primary antiphospholipid syndrome in mice by immunisation with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558–1563.
49. Mulla MJ, Salmon JE, Chamley LW, et al. A role for uric acid and the Nalp3 inflammasome in antiphospholipid antibody-induced IL-1 production by human first trimester trophoblast. PLoS One 2013; 8: e65237.
50. Juliana C, Fernandes-Alnemri T, Kang S, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287: 36617–36622.
51. Hu Y, Mao K, Zeng Y, et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol 2010; 185: 7699–7705.